Patients with hepatocellular carcinoma showing macroscopic vascular invasion have a poor prognosis. Sorafenib is the sole treatment option for these patients, with unsatisfactory response and survival benefit. Combined treatment with transarterial chemoembolization (TACE) plus external beam radiotherapy (RT) has shown promising results for these patients in observational studies.
L iver cancer is the second leading cause of cancer death worldwide, 1 with hepatocellular carcinoma (HCC) accounting for about 90% of all primary liver cancers. 2 By 2030, the annual number of new liver cancer cases worldwide is predicted to increase 35% from 2005 (when the number of new cases was 708 536), especially in Western Europe and North America. 3, 4 About half of patients with HCC receive a diagnosis when the cancer is at a locally advanced stage, often with macroscopic vascular invasion (MVI) bearing a poor prognosis with an expected median survival time of only 2 to 5 months without treatment. [5] [6] [7] [8] Sorafenib is the only evidence-based treatment option for this patient group. However, in a pooled analysis of 2 pivotal phase 3 trials, sorafenib prolonged the median survival of these patients by only 47 days compared with placebo. [8] [9] [10] With recent technological advances, external beam radiotherapy (RT) could be considered an alternative treatment option for patients with HCC. 11 Recent early-phase trials have demonstrated that RT can be safely and effectively delivered to locally advanced HCC, leading to sustained local control and survival rates higher than in historical controls. [12] [13] [14] The combined treatment of transarterial chemoembolization (TACE) and RT has shown promising radiologic response rates and improved overall survival with HCC and MVI in observational studies. [15] [16] [17] This randomized clinical trial assesses the efficacy and safety of TACE plus RT compared with sorafenib for patients with HCC and MVI.
Methods

Study Design and Participants
This study was a randomized, single-center, open-label clinical trial conducted at Asan Medical Center, Seoul, Republic of Korea. The trial protocol is available in Supplement 1. Eligible patients were aged 20 years or older and had a primary diagnosis of HCC with MVI. No patients had received previous therapy for HCC. Hepatocellular carcinoma was diagnosed by histologic findings and/or the American Association for the Study of Liver Diseases criteria. 18 The presence of MVI was assessed by 4-phase dynamic computed tomography (CT) using the following criteria: an intraluminal filling defect adjacent to the primary tumor in a portal and/or hepatic vein, an enhancement of the filling defect on the arterial phase, and a washout on the portal or delayed phases. Patients with HCC invading at least the first-or second-branch portal vein, with preserved unilateral portal blood flow, were included. All patients provided written informed consent before enrollment. This study was approved by the Asan Medical Center institutional review board. Eligibility criteria also included an Eastern Cooperative Oncology Group performance status score of 0 or 1; ChildPugh class A liver function; no extrahepatic metastasis detected on abdominal CT scan, chest CT scan, and whole-body bone scan; and adequate hematologic, hepatic, and renal function (hemoglobin level ≥8. 
Randomization
Between July 1, 2013, and October 31, 2016, all eligible patients were randomly assigned to receive sorafenib or TACE plus RT in a 1:1 ratio using an interactive web response system integrated with the electronic data capture system (Medrio Inc). Randomization was conducted within 1 week after eligibility confirmation, and treatments began within 1 week thereafter.
Interventions
Sorafenib was continuously administered orally as a standard 400-mg dose twice daily (800 mg/d). Patient visits were scheduled every 2 weeks for the first 6 weeks and every 3 weeks thereafter to monitor safety and drug accountability. Dose reductions and treatment interruptions were allowed according to drug-related toxicity grade as recommended. For the TACE procedure, after selective catheterization of the feeding artery, 2 mg/kg of cisplatin was infused as the chemotherapeutic agent. The feeding arteries were then embolized using an emulsion of 5 to 10 mL of cisplatin and iodized oil (Lipiodol Ultra-Fluide; Laboratoire Guerbet) mixture, followed by an absorbable gelatin sponge (Gelfoam; Upjohn). To minimize the risk of hepatic decompensation after TACE, gelatin sponge particle embolization was not performed according to the severity of portal blood flow impairment at the discretion of the investigator. Transarterial chemoembolization was repeated every 6 of the first 24 weeks and every 6 to 8 weeks thereafter.
External beam RT for vascular invasion began within 3 weeks after the first TACE. Gross tumor volume included vascular invasion and a 2-cm margin into the contiguous HCC at the end-expiratory phase of the CT image. Internal target volume was delineated as the sum of the individual gross tumor volumes, as defined within the gated respiration phases. Planning target volume was expanded to include a 0.7-cm margin from the internal target volume. The planned total dose to the planning target volume was 45 Gy with the fraction size of 2.5 to 3.0 Gy, using 6-, 10-, or 15-MV X-rays at 5 fractions per week with a linear accelerator (Varian Medical Systems).
17 A 3-dimensional conformal RT technique was used to determine radiation ports using a planning system (Eclipse, version 10.0; Varian), and the actual beam delivery was performed with a respiratory-gated beam delivery technique.
Outcomes and Assessments
The primary end point of the study was the 12-week progression-free survival (PFS) rate. Progression was defined as progressive disease by independent radiologic review according to RECIST, version 1.1, criteria 19 or death from any cause. Secondary end points were the 24-week PFS rate, 12-and 24-week radiologic response rates, 12-and 24-week treatment crossover rates, time to progression, time to treatment crossover, and overall patient survival. The overall treatment period was divided into 6-week cycles for the efficacy and safety assessment. Tumor measurements and response evaluations were conducted by an independent radiologist (S.J.L.) based on liver dynamic CT images at screening and every 6 weeks after randomization. A secondary radiologist in the central imaging core laboratory (Asan Image Metrics) performed an independent blinded image review at the end of the study without interfering with the primary judgment concerning disease progression and treatment decision. The radiologic response rate was defined as the proportion of patients with complete response or partial response. Treatment crossover was permitted after confirming disease progression during the initially assigned treatment. Adverse events were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.
After completion of the 24-week initial study period, patients continued treatment and were followed up for disease progression and overall survival until August 31, 2017. Curative surgical resection was allowed for patients with partial response after 24 weeks.
Statistical Analysis
The primary data set for efficacy analyses comprised all randomized patients (intention-to-treat analysis), and the analyses were performed by comparing the originally randomized treatment groups (ie, the sorafenib and TACE-RT groups). Assuming 12-week PFS rates of 50% for the sorafenib group 8, 9 and 80% for the TACE-RT group 17 plus a 2-sided 5% significance level, 90 patients were required to achieve 80% power based on a test for equality of proportions.
The χ 2 test or the Fisher exact test were used to compare the 12-and 24-week radiologic response rates between treatment groups, as appropriate. Survival curves for time-toevent variables were determined by the Kaplan-Meier method, and the log-rank test was used for treatment comparisons. The hazard ratio for survival and its 95% CI were calculated using a Cox proportional hazards regression model. All tests were 2-sided, and P < .05 was considered statistically significant. All statistical analyses were performed using SPSS Statistics, version 21 (IBM Corp).
Results
Study Population
Between July 1, 2013, and October 31, 2016, 90 patients were randomly assigned to receive sorafenib (45 participants) or TACE plus RT (45 participants), and they were included in the intention-to-treat analysis ( Figure 1) . Baseline characteristics were well balanced between the sorafenib and TACE-RT groups ( 
PFS and Response Rates at 24 Weeks
At week 12, a total of 5 patients had died and 27 patients had radiologic disease progression in the sorafenib group, while none had died and 9 had radiologic disease progression in the TACE-RT group. The 12-week PFS rate was significantly higher in the TACE-RT group than in the sorafenib group (86.7% vs 34.3%; P < .001) ( Table 2 and Figure 2A ). At 12 weeks, a radiologic response was achieved in 2 patients (4.4%) in the sorafenib group and 13 patients (28.9%) in the TACE-RT group (P = .002). After confirmation of radiologic disease progression, 20 patients (48.9% by Kaplan-Meier estimation) in the sorafenib group switched their treatment to TACE plus RT within 12 weeks, while no patients in the TACE-RT group switched their treatment to sorafenib (P < .001).
At week 24, a total of 11 patients had died and 36 patients had radiologic disease progression in the sorafenib group, while 7 had died and 19 had radiologic disease progression in the TACE-RT group. The 24-week PFS rate was significantly higher in the TACE-RT group than in the sorafenib group (55.6% vs 7.4%; P < .001) ( Table 2 and Figure 2A and B). A radiologic response was observed in 1 patient (2.2%) in the sorafenib group and 15 patients (33.3%) in the TACE-RT group (P < .001). In the sorafenib group, 34 patients (90.7% by Kaplan-Meier estimation) switched their treatment to TACE plus RT owing to disease progression within 24 weeks, while 9 (23.0%) in the TACE-RT group switched their treatment to sorafenib (P < .001) ( Table 2 and eTable 2 in Supplement 2).
The discordance rate between the primary and secondary radiologic review was 4.8% (4 of 83; P = .13) (eTables 3 and 4inSupplement 2), indicating low interrater variability with no effect on patient outcomes (eFigure 1 in Supplement 2). α-Fetoprotein levels decreased significantly at 24 weeks in the TACE-RT group only (eTable 5 and eFigure 2 in Supplement 2). Regardless of the extent of vascular invasion, those in the TACE-RT group showed significantly better median 24-week PFS than those in the sorafenib group ( 
Time to Disease Progression
During a maximum of 140 weeks of follow-up, disease progression occurred in 39 patients in the sorafenib group and 33 patients in the TACE-RT group (100% in the sorafenib group vs 83.8% in the TACE-RT group by Kaplan-Meier estimation; P < .001 ( Figure 2C ). The median time to progression was significantly longer in the TACE-RT group than in the sorafenib group (31.0 vs 11.7 weeks; hazard ratio, 0.28; 95% CI, 0.17-0.46; P < .001) ( Table 3) .
Overall Survival
The median overall survival was significantly longer in the TACE-RT group than in the sorafenib group (55.0 vs 43.0 weeks; hazard ratio, 0.61; 95% CI, 0.38-0.98; P = .04) ( Table 3 and Figure 2D ). The 48-week survival rates were 55.4% in the TACE-RT group and 44.4% in the sorafenib group. By the last follow-up, 18 patients were alive (6 in the sorafenib group and 12 in the TACE-RT group). All living patients in the sorafenib group had switched their treatment to TACE plus RT owing to disease progression. No patients continued to receive sorafenib treatment.
Curative surgical resection could be performed on 5 patients (11.1%) only in the TACE-RT group between 27 and 40 weeks owing to downstaging; 1 patient died at 51 weeks, and 4 were alive at the last follow-up, with an overall survival time of 119 to 149 weeks. A representative case is shown in eFigure 4inSupplement 2.
Safety
One patient assigned to the sorafenib group withdrew consent after randomization and did not receive treatment. Therefore, the safety analysis population comprised 89 patients who received the assigned treatments.
The overall incidences of adverse events were 93.2% in the sorafenib group (41 of 44 patients) and 91.1% in the TACE-RT group (41 of 45 patients) (eTables 6 and 7 in Supplement 2). Serious adverse events were reported for 5 patients in each group. A patient in the sorafenib group discontinued treatment because of severe mucositis. In the TACE-RT group, a transient grade 3 elevation in total bilirubin level was observed in 1 patient; however, this patient's treatment was discontinued owing to lung metastasis.
The actual mean daily dose of sorafenib was 739 mg. Overall, 14 of 44 patients (31.8%) in the sorafenib group required dose modiications for adverse events (eTable 8 in Supplement 2). In the TACE-RT group, for the first TACE, full-dose chemoembolization with cisplatin, iodized oil, and gelatin sponge cubes was performed for 29 patients (64.4%), and chemoembolization without gelatin sponge infusion was performed for 
8-10
Macroscopic vascular invasion is a prognostic factor for poorer overall survival among patients with HCC. [6] [7] [8] Even with sorafenib treatment, patients with HCC are prone to rapid progression of tumors. [8] [9] [10] In our study, the median time to disease progression was only 11.7 weeks with sorafenib, which was shorter than that of patients with advanced HCC treated with sorafenib in previous phase 3 trials ( ). Nevertheless, the median overall patient survival in the sorafenib group in our study (43 weeks) was similar to that in the SHARP trial (10.7 months) 10 and longer than that in the Asia-Pacific trial (6.5 months). 9 The fact that most of the patients in the sorafenib group switched their treatment to TACE plus RT after identifying disease progression (median, 13 weeks; 34 participants [90.7%] in 24 weeks) may explain these findings. To ensure that patients were not disadvantaged by participation, treatment crossover was allowed with disease progression. We reasoned that the high rate of treatment crossover might obscure any benefit of the initially assigned treatment if overall survival was chosen as the primary end point. Hence, we thought that PFS was the most appropriate primary end point. Nonetheless, overall survival in the TACE-RT group was significantly longer than in the sorafenib group, suggesting that it would be better to begin treatment with TACE plus RT than with sorafenib. Tumor invasion of portal veins not only promotes intrahepatic tumor spread but also rapidly decreases blood supply to the liver, causing an abrupt increase in portal pressure, resulting in rapid deterioration of liver function and increased risk of portal hypertensive complications. 17 This, in turn, may limit further treatment options. Because of the rapidity of HCC tumor thrombus progression, quick reduction in tumor thrombus volume is important to facilitate subsequent treatment of the primary tumor. However, sorafenib is only likely to delay tumor progression, and the incidence of objective responses is very low (2%-3.3%). 9, 10 Transarterial chemoembolization alone may also have limited efficacy in reducing the tumor thrombus. 15, 22 Although MVI is a route of distant tumor spread, intrahepatic vascular invasion is a local disease. A potent locoregional treatment may be better than systemic therapy before the diagnosis of distant metastasis. Owing to the advent of CT-based treatment planning, 3-dimensional conformal liver irradiation has become a feasible and safe technique for advanced HCC, allowing safe delivery of high tumoricidal doses of radiation that conform tightly to the tumor, with minimal risk of radiation-induced liver disease (<5%). 11, 12, 14 One of the primary indications for RT is the MVI of HCC. Radiotherapy has been shown to have objective response rates ranging from 39% to 62% in patients with HCC and MVI. 12, [23] [24] [25] [26] [27] Despite high local control rates by RT alone, failure outside the radiation field provides the rationale for combining regional or systemic treatments with RT. Especially, TACE is a proven treatment for locally advanced HCC, and TACE and RT may complement each other; focal field RT targeting the MVI may relieve intravascular tumor growth and maintain portal blood flow, allowing the maintenance of liver function, limiting intrahepatic tumor spread, and thereby allowing additional TACE. 25,26,28 Furthermore, as shown in our study, some patients can receive subsequent curative surgical resection owing to downstaging by TACE plus RT, enabling long-term patient survival. Previous studies have raised caution regarding the risk of TACE-induced liver failure in patients with HCC and MVI. 2 However, in our trial, no patients in the TACE-RT group discontinued treatment for adverse events. Our study may not be large enough to accurately establish the incidence of adverse events. However, considering the dismal prognosis, the superior efficacy of TACE plus RT vs sorafenib may justify its use for these patients.
Limitations
This study has potential limitations. First, the nature of the treatments under investigation did not permit blinding. As an open-label trial, this study may be prone to bias. Although radiologic progression was assessed by an independent radiologist according to the RECIST criteria, blinded assessment was not feasible owing to the different image responses after treatment with sorafenib and TACE. However, objective clinical outcomes, such as overall survival, are unlikely to be biased by unblinding. 29 Second, the generalizability of our results may be limited. The predominant population (76 [84.4%]) in this study had hepatitis B virus-associated HCC; thus, the treatment strategy described may not be extrapolatable to patients with HCC not associated with hepatitis B virus.
Conclusions
This randomized clinical trial demonstrated that, for patients with advanced HCC showing MVI, the combined treatment of TACE and RT was well tolerated and provided an improved PFS, objective response rate, time to progression, and overall survival compared with sorafenib treatment. Transarterial chemoembolization plus RT also provided a chance for curative resection in some patients. Further studies are needed to confirm our findings and, given the poor overall patient survival even with TACE plus RT, to further improve patient outcome. Newer locoregional therapies (LRTs), including drugeluting beads for TACE and internal radiotherapy with transarterial yttrium-90-coupled microspheres has spurred considerable interest, although without a definitive survival advantage to date relative to proven treatments. Furthermore, with advanced-stage HCC, no survival advantage vs sorafenib has been shown with these therapies alone or in combination with systemic therapies, 1 although additional phase 2 and phase 3 trials are ongoing for both TACE and yttrium-90 with sorafenib (NCT01126645 and NCT01556490). As the available armamentarium has evolved and grown, so has interest in combining these therapies to maximize patient benefit. Transarterial chemoembolization with ablation, for example, has shown promise in prospective trials at improving local disease control and overall survival for earlystage HCC. 6 It is fitting, therefore, that interest in multimodal therapy to improve the dismal prognosis of advanced-stage HCC would naturally follow. Specifically, portal venous invasion (PVI) has consistently been associated with poorer prognosis, with or without extrahepatic disease. 5 Existing treatments demonstrate poor efficacy for HCC with PVI, with subgroup analyses in early major prospective trials showing modest, if any, benefits of therapy beyond the natural history of the disease. 5 In this issue of JAMA Oncology, Yoon et al 7 have now provided much-needed prospective data showing a potential signal for improved outcomes in patients with HCC and PVI treated aggressively with locoregional therapy using TACE and XRT. Using a therapeutic strategy including serial TACE with early XRT compared with systemic therapy with sorafenib, they demonstrated a significantly improved primary end point for 12-week progression-free survival (86.7% vs 34.3%; P < .001). In addition, secondary end points of radiologic response rate (33.3% vs 2.2%; P < .001), median time to progression (31.0 vs 11.7 weeks; P < .001), and overall survival (55.0 vs 43.0 weeks; P = .04) were all improved in those treated with LRT. Although impressive, the outcomes and study design have notable caveats that are important to consider if the data are to be extrapolated for routine practice. The sample size included only 90 patients, and the proportion of participants with cirrhosis was not reported, a factor that may affect the safety of aggressive LRT. Moreover, the cohort included mostly patients with hepatitis B virus-related liver disease, a subset of patients who potentially have less favorable outcomes with sorafenib treatment relative to those with hepatitis C virusrelated HCC. 1 Finally, the median time to progression in the sorafenib arm (11.7 weeks) was shorter than what has been reported in other trials. Thus, the relevance of the findings to other patient populations must be made cautiously. The TACE protocol used in the study by Yoon et al 7 included a cisplatin infusion followed by cisplatin and gelatin sponge chemoembolization, with additional bland arterial embolization performed subjectively based on the degree of PVI.
Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma
Transarterial chemoembolization was performed every 6 weeks, with a median of 4 treatments. With respect to generalizability, cisplatin is not universally used for TACE, either owing to availability or practice patterns. Moreover, many centers perform repeat TACE only if needed based on residual disease on results of cross-sectional contrast-enhanced imaging, rather than in a scheduled fashion. 
Confidentiality
The information contained in this document is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Institutional Review Board or Independent Ethics Committee. The information is only to be used by you in connection with authorized clinical studies described in the protocol. You should not disclose any of the information to others without written authorization from the investigator, except to the extent necessary to obtain informed consent from those persons to whom the drug may be administered. -an enhanced filling defect on arterial phase and a washout on portal/delayed phase -reserved unilateral portal blood flow at least in partial 6) HCC > 1 cm and the extent of tumor < 50% of liver volume 7) Adequate hematologic function -hemoglobin ≥ 8.5 g/dL -absolute neutrophil count ≥ 750/mm 3 -platelet ≥ 30,000/mm 3 -prothrombin time international normalized ratio ≤ 1.5
Confidential Version 3.3 8) Adequate hepatic and renal function -aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 10 x upper limit of normal (ULN) -albumin ≥ 2.8 g/dL -total bilirubin ≤ 3 mg/dL -serum creatinine < 1.5 mg/dL 6) Patient understand the clinical trial protocol and is willing to provide written informed consent to participate in the study
# Exclusion criteria:
Patients will be excluded from the study for any of the following reasons: 1) Treatment history of prior TACE, radiotherapy, or sorafenib 2) Extrahepatic metastasis 3) A complete obstruction of portal flow or hepatic outflow 4) Extent of tumor > 50% of liver volume 5) Uncontrolled ascites and hepatic encephalopathy 6) History of liver or other organ transplantation 7) Active gastric or duodenal ulcer within 3 months 8) Uncontrolled severe medical comorbidity 9) Infection with human immunodeficiency virus 10) Pregnant or breastfeeding women 11) Women of childbearing ages unless using effective contraception 12) Double primary malignancy (a history of treated malignancy (other than HCC) is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding two years.) 13) Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with the completing the study.
Clinical Research Protocol -START Study
Principal Investigator: Lim, Young-Suk
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Statistical Analyses
Sample Size Justification Sample size required for this study was estimated with following assumptions, -Estimated progression-free survival (PFS) rates at 12 weeks for sorafenib group = 50% -Estimated PFS rates at 12 weeks for TACE+RT group = 80% -Power (1-beta) = 0.8 -Alpha error = 0.05 -Drop-out rate = 10% -The primary endpoint is PFS rates at 12 weeks in all randomized subjects. For estimating the difference in PFS rates between arms, the sample size was 90 subjects in total and 45 subjects per arm, based on a test for equality of proportions.
Statistical Analytic Plan
The primary dataset for efficacy analyses is defined as all randomized patients (intention-to-treat [ITT] analysis). Progression is defined as progressive disease (PD) by independent radiologic review according to RECIST criteria (version 1.1) or death from any cause. Patients who discontinue the initially-assigned treatment without PD or death will be censored at the time of discontinuation. Efficacy analyses will be performed comparing the originally randomized treatment groups, sorafenib and TACE+RT. Safety profiles will be evaluated in the modified ITT population including the patients who received at least one dose of sorafenib or at least one session of TACE treatment. Interim analysis is not planned. Survival curves for time-to-event variables, such as PFS rate, time to radiologic progression, time to treatment-crossover, and overall survival rate, will be determined by the Kaplan-Meier estimation, and the log-rank test will be used for treatment comparisons. The response rates at 12-and 24-weeks in the treatment groups will be compared using Chi-square test or Fisher's exact test, as appropriate. An exploratory Cox proportional-hazards model will be used to evaluate the interaction between important baseline characteristics and the effect of treatments on overall survival. Hazard ratio (HR) and 95% confidence interval (CI) will be calculated for the TACE+RT group relative to the sorafenib group using a Cox proportional-hazards model. The tests performed will be 2-sided, and P values <0.05 will be considered statistically significant. All statistical analyses will be performed using SPSS Statistics version 21 (IBM, Armonk, NY).
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Time & Event Table   Assessment 1. Physical examination: to check the performance status, other significant signs 2. Vital signs: blood pressure, pulse rate, body weight, and height (The height is scheduled to be measured once at the screening) 3. Hematology: hemoglobin, red blood cell (RBC), white blood cell and differential white blood cell count, and platelet count 4. Chemistry: Sodium, potassium, BUN, creatinine, total protein, albumin, AST, ALT, ALP, total/direct bilirubin, amylase, phosphorus, calcium, and creatinine phospho-kinase (CPK) ........................................................................................................... 19  Appendix ............................................................................................................... 
Study Objectives and Background
Study Objectives
The objective of this study is to compare the efficacy and safety of the combined treatment of transarterial chemoembolization (TACE) plus radiotherapy (RT) compared with sorafenib treatment for hepatocellular carcinoma (HCC) with major vascular invasion.
Primary Endpoint
-progression-free survival rate at 12 weeks
Secondary Endpoints
1) progression-free survival at 24 weeks 2) radiologic response rates at 12-and 24-weeks 3) treatment-crossover rates at 12 and 24 weeks 4) time to disease progression during up to 4-years of follow-up 5) time to treatment-crossover during up to 4-years of follow-up 6) overall patient survival during up to 4-years of follow-up
Background
HCC is the sixth most common cancer worldwide and the second most common cause of cancer-related death (1) . The greatest burden of HCC comes from developing countries, with 80% of occurrences originating in Asia and Africa. However, HCC has been the fastest-rising cause of cancer-related deaths in Western countries during the past two decades and is expected to increase further in the next decade (2) (3) (4) . Approximately 50% of the patients with HCC are already diagnosed as locally advanced HCC with major vascular invasion at the time of diagnosis. Portal vein, hepatic vein, or inferior vena cava tumor thrombus often cause extensive intrahepatic dissemination of the tumor through these vessels, can decrease blood supply to the normal liver, and finally cause portal hypertension resulting in the rupture of collateral vessels, ascites, hepatic encephalopathy, and deteriorating liver function (5, 6) . This, in turn, may limit further treatment options in patients with HCC. The only evidence-based treatment option for these patients is sorafenib in many guidelines for HCC, including that of the American Association for the Study of Liver Disease (AASLD) (Figure 1 ) (7).
Confidential Version 3.3 Although sorafenib has been approved as a standard systemic therapy for patients with advanced HCC, the objective response rate is somewhat disappointing at 2-5% (8,9). Furthermore, median time to progression was only 2.8 months and the prolongation of patients' survival was 2.5 months in a study of the Asia-Pacific region (9) . Therefore, even after the introduction of sorafenib in Korea in 2009, the frequency of the use of this agent as a first-line therapy for advanced HCC has not been high. Recent improvement in radiotherapy techniques, including 3-dimensional conformal radiotherapy (3D-CRT) and image-guided radiotherapy, as well as information on partial volume liver tolerance, has allowed the delivery of radiation doses to these tumors that are higher than previously thought possible, allowing radiotherapy to be used as an alternative treatment option for HCC (10, 11) . One of the primary indications for radiotherapy has been the major vascular invasion of HCC; and good responses and promising outcomes have been obtained usually combined with TACE (12-15). Because major vascular invasion is a major obstacle to performing TACE, focal field radiotherapy targeting the vascular invasion, may be a good treatment option. The rationale for this combined approach is that focused on vascular invasion may decrease intravascular tumor growth and maintain portal blood flow, allowing the maintenance of normal liver function, limiting intrahepatic tumor spread, and thereby allowing additional TACE (13, 16) . However, evidence level to support combined treatment with TACE plus radiotherapy in the patients is low, and there have been no randomized trials. Thus, we conduct a randomized phase 2 trial comparing combined TACE plus external beam radiotherapy with sorafenib with HCC and major vascular invasion.
Study Design
Prospective randomized, active-controlled, open-label, single-center trial
Projected Duration of the Study
From the date of IRB approval to 31 DEC 2017 Initial assessment period: 24 weeks from randomization Follow-up assessment period: up to 4 years from randomization The duration of the study could be extended according to the enrollment rate. (1) an intraluminal filling defect adjacent to the primary tumor in portal vein, hepatic vein, and/or inferior vena cava (2) an enhancement of the filling defect on arterial phase and a washout on portal/delayed phases. (9) Infection with human immunodeficiency virus (10) Pregnant or breastfeeding women (11) Women of childbearing ages unless using effective contraception (12) Double primary malignancy (a history of treated malignancy (other than HCC) is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding two years) (13) Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with the completing the study
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Study Procedures and Methods
Assignment of subjects
All eligible patients are randomly assigned to receive 400 mg twice a day of sorafenib or combined TACE plus RT during the study period.
Method of assigning patients to treatment groups and randomization
(1) Sorafenib group: sorafenib (800 mg/day) (2) TACE plus RT group (3) The randomization process -After making the four blocks-sized randomization list, we will make it be connected with the electronic Case Report Form (eCRF). Eligible subjects for the study will be randomized in a 1:1 ratio to each group, using the Interactive Web Response System (IWRS). The IWRS will be integrated with the electronic data capture (EDC) system (Medrio, Inc, San Francisco, CA, eClinical & Electronic Data Capture in the Cloud. Available at http://medrio.com/). Site personnel (Principal Investigator, Sub-Investigator or Study Coordinator) will access the IWRS through the EDC system. Patient randomization number and assignment to treatment arm will be provided by this IWRS/EDC system. (4) Allocated patients -Number of total population -90 (sorafenib: 45, TACE+radiotherapy: 45) (5) Randomization method
-As an open-label trial, all the doctors and patients know assigned treatments. (6) Stratification -Stratification will not be performed during randomization process.
Treatment
Sorafenib 1) Medication of sorafenib
 Sorafenib is administered orally as a standard 400 mg dose twice daily (800 mg/day) as a continuous dose.  Sorafenib will be taken 1 hour before meals or at least 2 hours after meals.  Sorafenib medication is continued until disease progression unacceptable toxicity, death, withdrawal of consent, or decision by the investigator.
2) Dose modification and treatment interruptions
 Treatment interruptions and dose reductions (first 200 mg twice daily, then 200 mg once daily) are allowed for drug-related toxicity.  The reduced dose can be re-escalated to the standard dose according to the investigator's discretion.
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Transarterial chemoembolization 1) TACE procedure
 Selective catheterization of the feeding artery will be performed using a 2.0 to 2.8 F microcatheter.  2 mg/kg cisplatin (Dong-A Pharmaceutical, Korea) will be infused as the chemotherapeutic agent.  The feeder arteries will be then subsequently embolized by using an emulsion of 5 to 10 mL of cisplatin and iodized oil (Lipiodol Ultra-Fluide; Laboratoire Guerbet, Aulnay-sousBois, France) mixture, and finally by absorbable gelatin sponge (Gelfoam; Upjohn, Kalamazoo, MI).

The feeder arteries will be embolized until arterial flow stasis is achieved.  To minimize the risk of post-TACE hepatic decompensation, gelatin sponge particle embolization will not be performed according to the severity of portal blood flow impairment at the discretion of the investigator.  TACE will be repeated every 6 weeks for the first 24 weeks, and every 6 to 8 weeks thereafter.  TACE can be suspended if there is no longer residual viable HCC at the discretion of the investigator.
External beam radiotherapy 1) Simulation process
 Patients are immobilized with a vacuum cushion in the supine position before CT simulation.  Free-breathing 4-dimensional (4D) CT scanning is performed using a 16-slice CT system.  To analyze the patients' breathing patterns, a Real-time Position Management respiratory gating system is used.  All CT datasets are sorted into 10-phase bins that corresponded to the respiratory phase, using 4D imaging software.
2) Delineation of the target volume and orangs at risk
 Every contouring is delineated on end-expiratory phase (phase 50%) CT images.  The gross tumor volume (GTV) includes vascular invasion and a 2-cm margin into the contiguous HCC. The GTV can consist of the entire HCC and vascular invasion at the discretion of the investigator.  The clinical target volume (CTV), which is an additional margin for the subclinical tumor extension, is not considered as a target volume in this study.  The internal target volume (ITV) is delineated as the sum of the individual GTVs, as defined within the gated phases of respiration (usually 30-70% phase).  The planning target volume (PTV) is expanded to include a 0.7-cm margin from the I T V.  Organs at risk (OARs): the whole and normal liver, both kidneys, spinal cord, duodenum, and stomach are delineated and 3-dimensionally reconstructed.
3) Treatment planning
 3D-conformal radiotherapy technique is used to determine target volumes, radiation ports, and dose prescriptions by using a 3D radiotherapy planning system.  Dose-volume histogram (DVH) is used to define the tumor dose and dose for normal organs.  Either 6 MV, 10 MV, or 15 MV photon energies can be used for treatment planning.
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Version 3.3  Static radiation beams are primarily used for treatment. (Intensity modulated radiotherapy is not a primary treatment method in this study.)  The dose per fraction to the PVT is 2.5 to 3 Gy at 5 fractions per week.  The target dose is 45 Gy, however, the total dose can be reduced as low as 30 Gy according to the liver function, liver volumes, or the maximum dose to the stomach/duodenum during the planning process.  The general prescription guideline is as follows:
-the normal liver treated with more than 50% of prescribed dose should be less than 50% of the normal liver volume (V50% < 50%).
-the volume of the normal liver that was damaged by irradiation is defined as the fraction volume of normal liver that received more than 30 Gy (V30 Gy), with no more than 30% of the normal liver exposed to more than 30 Gy (V30 Gy ≤ 30%).
-the maximum dose for the stomach or duodenal walls are 30 G y.
4) Radiation therapy in treatment room
 Radiation beams are delivered by a linear accelerator.  Actual beam delivery is performed with a respiratory-gated beam delivery technique.  Image guidance is performed in two stages before administering each fraction of radiotherapy using On-Board Imager.
-First, cone-beam CT is done and 3D matching is performed. -Second, gated fluoroscopy is performed in the anterior-posterior and lateral directions to confirm the internal surrogate positions at the end-exhale phase.  During radiation beam delivery, respiratory patterns is monitored by the Real-time Position Management system. 
5) Prophylactic anti-viral therapy
Evaluation of the subjects 1) Regular evaluation
 All patients undergo regular laboratory assessments according to the protocol.  For response evaluation, dynamic liver CT is checked in every 6 weeks after treatment start.  Dynamic liver MRI can be optionally used for further response evaluation.  In case of tumor progression or recurrence, the timing of the examination may be frequently checked at the discretion of the investigator.  More examinations (e.g. chest x-ray, chest CT, whole body bone scan, abdominal ultrasonography, PET scan, etc.) can be performed if needed.
2) Response evaluation

The standard images for response evaluation is dynamic liver CT.
Tumor measurements and response evaluation will be conducted by an independent radiologist  If the patient is not diagnosed as tumor progression and died unrelated to treatment toxicity, it is defined as progressive disease separately from RECIST by protocol-defined criteria.
Safety Evaluation
As sorafenib, TACE, and radiotherapy are ones of the standard treatment of HCC, their side effects and adverse events have been known well. Therefore, investigators will individually evaluate the well-known side effect, common side effects and unpredictable side effects that have not been reported yet.
Definition of Adverse Events
All adverse events will be assessed and recorded on the AE CRF page by the investigator. An adverse event (AE) is any untoward medical occurrence in a study patient, regardless of the potential relation with the use of a study drugs.
Assessment of AEs
All AEs and SAEs occurring after initiation of clinical trial and until the end of follow-up/final visit should be recorded in the CRF.
Severe Adverse Events (SAEs)
A serious adverse event is any untoward medical occurrence that, at any dose:  Death or life-threatening events  Requiring hospitalization or prolongation of existing hospitalization  Persistent or significant disability/incapacity  Development of fetal anomalies Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline is not considered a SAE
Reporting Procedure
The principle investigator and sub-investigators have to notify IRB all SAEs during the study regardless of causal relationship. They must fax or e-mail the SAE form to the principal investigator and Asan Medical Center IRB within 24 hours of the investigator's acknowledgement of the event.
All the information about serious adverse events should be reported to the principal investigator and IRB until they are completely resolved.
Intensity of AE
All AEs will be graded according to the Common Terminology Criteria of Adverse Event (CTCAE), version 4.03 grading scale.
Confidential
Causal Relationship of AE
The following categories and definitions of causal relationship to the study drug should be used for = 50% -Estimated PFS rates at 12 weeks for TACE plus radiotherapy group according to our previous observational study (15) = 80% -Power (1-beta) = 0.8 -Alpha error = 0.05 -Drop-out rate = 10% * The primary endpoint is PFS rates at 12 weeks in all randomized subjects. For estimating the difference in PFS rates between arms, the sample size was 90 subjects in total and 45 subjects per arm, based on a test for equality of proportions.
Statistical Analytic Plan
The primary dataset for efficacy analyses is defined as all randomized patients (intention-to-treat [ITT] analysis). Progression is defined as progressive disease (PD) by independent radiologic review according to RECIST criteria (version 1.1) or death from any cause. Patients who discontinue the initially-assigned treatment without PD or death will be censored at the time of discontinuation. Efficacy analyses will be performed comparing the originally randomized treatment groups, sorafenib and TACE+RT. Safety profiles will be evaluated in the modified ITT population including the patients who received at least one dose of sorafenib or at least one session of TACE treatment. Interim analysis is not planned.
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Survival curves for time-to-event variables, such as PFS rate, time to radiologic progression, time to treatment-crossover, and overall survival rate, will be determined by the Kaplan-Meier estimation, and the log-rank test will be used for treatment comparisons. The response rates at 12-and 24-weeks in the treatment groups will be compared using Chi-square test or Fisher's exact test, as appropriate. An exploratory Cox proportional-hazards model will be used to evaluate the interaction between important baseline characteristics and the effect of treatments on overall survival. Hazard ratio (HR) and 95% confidence interval (CI) will be calculated for the TACE+RT group relative to the sorafenib group using a Cox proportional-hazards model. The tests performed will be 2-sided, and P values <0.05 will be considered statistically significant. All statistical analyses will be performed using SPSS Statistics version 21 (IBM, Armonk, NY).
Measurement of Compliance
The importance of compliance with the sorafenib will be emphasized at each visit. Adherence to sorafenib will be assessed by returned pill counts and patient survey. A record of this reconciliation must be maintained using the accountability forms, and any issues of non-compliance discussed with the subject.
Discontinuation and Withdrawal
Subjects may be withdrawn from the study at the investigator's discretion in any of the following instances:
 Development of a toxicity or adverse event which warrants discontinuation of the drug or intervention The subjects refuse the administration of the study drugs/intervention or safety tests

The subjects withdraw the agreement of participation of the trial Treatment after discontinuation or withdrawal will be determined by the investigator. In case of discontinuation or withdrawal due to adverse events or safety issue, subjects should be followed until full recovery and the events should be recorded in CRFs.
Protection of the Subjects
The investigational institutions should make sure that the necessary personnel and facilities to conduct the study are appropriately provided. The investigators should do their best for the safety of the study subjects. If serious adverse events occur during the trial, the investigators should notify IRB after taking adequate therapeutic measures. The responsible conduct of the study will be regularly monitored by the Human Research Protection Center of each participating sites.
Informed Consent, Agreement of Compensation, Post-Study Treatment
Patient Information and Informed Consent
The investigator is responsible for obtaining written informed consent from each participant after adequate explanation of the aims, methods, objectives, and potential hazards of the study and before undertaking any study-related procedures. The investigator must use the IRB-approved consent form for the written informed consent. Each informed consent will be appropriately signed and dated by the subject or the subject's legally authorized representative and the person obtaining the consent.
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A signed copy of the informed consent and any additional patient information must be given to each patient or the patient's legally accepted representative. If the subject or representative cannot read, an impartial witness is needed.
Compensation Available to the Patients in the Event of Trial Related Injury
In the event of health injury associated with this trial, the sponsor is responsible for compensation based on the contract.
Treatment of the Subjects after the End of the Clinical Trial
The subjects who have fulfilled the study would follow the standard treatment of liver cirrhosis. The subjects who are terminated in the middle of the study should receive other appropriate surveillance of HCC. After detection of HCC, treatment will be determined by the subjects' clinical status and at the physician's discretion.
Additional Considerations for the Study
Compliance and modification of the clinical trial protocol
This study must be conducted according to the clinical trial protocol, including written informed consent approved by the IRB. All protocol modifications should be upfront discussed between the investigators. All protocol modifications, except those intended to reduce immediate risk to subjects, should be submitted to and approved by the IRB. Approvals must be obtained before changes can be implemented. In the event that modification applied to prevent immediate damage to the subjects before the IRB approval, they should be reported to the IRB as soon as possible.
Monitoring
Assigning the Data Safety and Monitoring Committee (DSMB) in charge of this trial, the DSMB will regularly visit and monitor the study sites before starting the study and during the whole study period. The monitor is responsible for routine review of the CRFs at regular intervals throughout the study to verify adherence to the protocol and the completeness, consistency, and accuracy of the data being entered on them. The monitor should have access to any subject records needed to verify the entries on the CRFs. The investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits are resolved.
Storage of the Documents and Data
The investigator must maintain all the documents and records of this study to be adequate and accurate, and should subsequently verify them. The investigator is responsible for maintaining and providing of the essential documents. The essential documents mean ones that allow evaluating conduct of the clinical trial. The clinical trial essential document will contain the protocol/amendments, CRF and query forms, IRB approval with correspondence, informed consent, and monitoring records and other appropriate documents and correspondence. Subject clinical source documents contain all the observed date, the records of clinical trial activities and all the reports and records for assessment and reconstruction of the clinical trial. Therefore subject clinical source documents should include the records of all the procedures conducted by the clinical trial protocol.
All clinical study documents must be retained by the investigator until at least 3 years after the end of the study. 
Confidentiality of the Data and Records of the Subjects
